Intellia Therapeutics (NTLA) Cash from Investing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Investing Activities data on file, last reported at $66.3 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 29.7% year-over-year to $66.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.0 million (down 6.53% YoY) and the FY2025 annual result came in at $228.0 million, up 81.6% from the prior year.
• Cash from Investing Activities advanced to $66.3 million in Q1 2026 per NTLA's latest filing, from $27.5 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $151.6 million in Q4 2024 and bottomed at -$122.2 million in Q1 2023.
• The 5-year median for Cash from Investing Activities is $45.9 million (2023), against an average of $32.3 million.
• The widest annual swing landed in 2023, when Cash from Investing Activities tumbled 357.51%; it then soared 1498.51% in 2025.
• Tracing NTLA's Cash from Investing Activities over 5 years: stood at -$30.2 million in 2022, then surged by 252.36% to $45.9 million in 2023, then surged by 229.93% to $151.6 million in 2024, then slumped by 81.83% to $27.5 million in 2025, then jumped by 140.83% to $66.3 million in 2026.
• Per Business Quant, the three latest NTLA Cash from Investing Activities figures stand at $66.3 million (Q1 2026), $27.5 million (Q4 2025), and -$741000.0 (Q3 2025).

Peer Comparison